| Trial Identifier: | 208887 Sub Study 2 |
| Sponsor: | GlaxoSmithKline |
| Start Date: | November 2019 |
| Primary Completion Date: | April 2025 |
| Study Completion Date: | March 2027 |
| Condition: | Myeloma |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| Country | Location |
|---|---|
| Australia, VIC | Fitzroy, VIC, Australia, 3065 |
| Australia, VIC | Melbourne, VIC, Australia, 3000 |
| Canada, BC | Vancouver, BC, Canada, V5Z1M9 |
| Canada, Ontario | Toronto, Ontario, Canada, M5G2M9 |
| France | VILLEJUIF CEDEX, France, 94805 |
| Germany, Hamburg | Hamburg, Germany, 22083 |
| Netherlands | UTRECHT, Netherlands, 3584CX |
| Spain | Pamplona Navarra, Spain, 31008 |
| Sweden | Stockholm, Sweden, SE-141 86 |
| United States, GA | Atlanta, GA, United States, 30322 |
| United States, WI | Madison, WI, United States, 53792 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2026 Pharma Intelligence UK Limited (Citeline), a Norstella company